Case Comprehensive Cancer Center Researchers Receive Funding for Promising Childhood Cancer Research
 |
|
|
Reshmi Parameswaran
|
Reshmi Parameswaran, PhD, Case Comprehensive Cancer Center, assistant professor of hematology and oncology, was awarded $330,000 to develop safer cancer therapies for children using their own immune cells, helping avoid the significant physical and emotional consequences that can result from other, more toxic treatments.
|
|
|
Nora Nock
|
Also, Nora L. Nock, PhD, Case Comprehensive Cancer Center, associate professor of epidemiology and biostatistics, has received a $50,000 grant to conduct a pilot study of 'cybercycling' (stationary cycling with interactive video gaming) to improve fitness and quality of life in adolescent and young adult cancer survivors. Nock will also evaluate the potential of 'cybercycling' to increase motivation to exercise and improve body composition, cognition, and sleep, as well as reduce fatigue and depression. more>
|
Sloan Receives Neuro-Oncology Award
Helio/HemOnc Today - Oct 7, 2016
|
|
|
Andrew Sloan
|
Andrew Sloan, MD, Case Comprehensive Cancer Center, director of the Brain Tumor and Neuro-Oncology Center at University Hospitals Cleveland Medical Center, received the Neuro-Oncology Award at the Annual Meeting of the Congress of Neurological Surgery. The award recognizes Sloan's work related to immune-gene therapy of gliomas.
Dr. Sloan also serves as chair of neurosurgical oncology at UHCMC,
vice chair of the department of neurological surgery at University Hospitals, and professor of neurosurgery at Case Western Reserve University School of Medicine.
|
7th Great Lakes Nuclear Receptor Conference
Registration is open for the 7th Great Lakes Nuclear Receptor Conference. This two-day event will be held October 19-20 at the Tinkham Veale University Center on Case Western Reserve University campus.
The program will feature talks from top researchers in this field, including keynote speakers Dr. Lorraine J. Gudas from Weill Cornell Medical College of Cornell University and Dr. Christopher Glass, from University of California, San Diego. The conference will touch on topics such as nuclear receptors in cancer, genome-wide nuclear receptor action, non-classical mechanism of receptor action, structure and cellular functions, and nuclear receptors and metabolism.
Contact conference organizers, Noa Noy, David Danielpour, Hannelore Heemers, with any questions.
|
NCCN 22nd Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care™
The National Comprehensive Cancer Network (NCCN) Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care attracts more than 1,500 registrants from across the United States and the globe including oncologists (in both community and academic settings), oncology fellows, nurses, pharmacists, and other health care professionals involved in the care of patients with cancer. Respected opinion leaders present the latest cancer therapies and provide updates on selected NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), the data upon which the NCCN Guidelines® are based, and quality initiatives in oncology. Topics change annually but focus on the major cancers and
supportive care areas.
The Annual Conference General Session begins on Thursday, March 23 at 8:00 AM and concludes on Saturday evening, March 25. This year's agenda will include more than 25 educational sessions featuring the latest advances in oncology care, plus interactive patient case studies & roundtable discussions.
This conference (with the exception of the NCCN Roundtable Discussions) will be designated for AMA PRA Category 1 Credit™ for physicians and certified for credit for nurses and pharmacists.
Registration Waiver/Discounts for NCCN Member Institutions
Registration fee is waived for NCCN Member Institution junior faculty (with a title of Assistant Professor or below). NCCN also extends a 50% discount off the registration fee to staff employed at NCCN Member Institutions. Interested individuals should e-mail Liz Rieder at rieder@nccn.org to learn more about how to apply for these discounts.
Call For Abstracts
The NCCN fifth annual General Poster Session will take place during the NCCN 22nd Annual Conference. Submissions will be accepted from academic institutions, teaching and community hospitals, or industry. Both NCCN and non-NCCN institutions may participate. Research may fall into one of the general categories below:
- Clinical Oncology (all phases)
- Pre-Clinical Oncology
- Epidemiology/Risks
- Correlative/Genomic
- Best Practices in Implementation and Use of Clinical Practice Guidelines
- Quality Improvement
- Outcomes and Health Services Research
- BIOinformatics/Information Technology Sciences
Abstracts are due on Sunday, November 6, 2016.
|
| Case program could ID recurring tumors
Crain's Cleveland Business - Oct 9, 2016
Increased blood vessels and swelling in the scan of a brain cancer patient who has undergone radiation treatment could be the effects of radiation or a recurring tumor.
Clinicians can have trouble differentiating between the two conditions, which have far different treatments.
In an effort to help diagnose these visually indistinguishable images, researchers at Case Western Reserve University created a computer program that can more accurately read those same magnetic resonance images (MRI), according to a new study...The program model, dubbed NeuroRadVision, obtained an accuracy of 80%, while radiologists in the study looking at the same scans the computer analyzed had accuracy rates roughly around 50%, said Pallavi Tiwari, Case Comprehensive Cancer Center, assistant professor of biomedical engineering at CWRU and leader of the study...NeuroRadVision is able to zoom into the pixels, densities and minute details of the same scan clinicians look at, said Anant Madabhushi, Case Comprehensive Cancer Center, professor of biomedical engineering at CWRU and the study's co-author..."Instead of having to operate to say, 'Oh, you have radiation necrosis or you have a recurrent tumor,' we could spare them that and then be able to direct their treatment based on whichever one it is," said Lisa Rogers, Case Comprehensive Cancer Center, CWRU neurology professor and medical director of the Neuro-oncology Program at University Hospitals Cleveland Medical Center. Rogers, also a co-author on the paper, said she "definitely" sees NeuroRadVision's direct applications for patients and hopes to be able to use the technology in the future.
|
The Cancer Therapy Advisor - Oct 7, 2016
The vaccine IMA901 did not improve overall survival when added to sunitinib as a first-line treatment for patients with metastatic renal cell carcinoma (RCC), according to a study published in
The Lancet Oncology (Rini BI. Lancet Oncol. 2016).
Researchers led by
Brian Rini, MD, Co-Leader, GU Malignancies Program of the Case Comprehensive Cancer Center and staff physician at the Cleveland Clinic Taussig Cancer Center in Ohio, examined the data of 1171 patients with treatment-naive, histologically confirmed metastatic or locally advanced RCC in the open-label, randomized, controlled, phase 3 IMPRINT (IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma; ClinicalTrials.gov Identifier: NCT01265901) trial.
|
| Beyond Ben Stiller's Beloved PSA, Prostate Cancer Screening Must Improve
Forbes.com - Oct 7, 2016
On Tuesday, Ben Stiller posted an essay on the website Medium with the provocative title "The Prostate Cancer Test That Saved My Life," explaining that his doctor started monitoring levels of prostate-specific antigen (PSA) in his blood when he was 46...
Stiller's 7 score, determined from an MRI and biopsy, was most definitely in the gray area. This is where the shortcomings of PSA testing become all too evident, leaving many men facing the uncertainty of whether or not they should aggressively treat their tumors, like Stiller did, or continue to watch them, says Lee Ponsky, Case Comprehensive Cancer Center, chief of the division of urologic oncology at University Hospitals Seidman Cancer Center in Cleveland. "One of the challenging parts of prostate cancer is we have options," Ponsky says. "That often creates a huge amount of anxiety for patients."
|
Family Circle - Oct 7, 2016
Find a multidisciplinary cancer center where you can meet with medical, surgical and radiation oncologists all under one roof. "Cancer is not straightforward and requires the input of three different types of doctors," notes Alberto Montero, MD, Case Comprehensive Cancer Center, a breast medical oncologist with the Cleveland Clinic. Having them all in the same facility not only eases communication between the doctors but also expedites getting information to you. "You want to see all of these doctors, preferably on the same day," says Montero, "so in one visit you can get a good idea of what your treatment is going to entail."
|
Nature.com - Sep 14, 2016
According to
Jorge Garcia, Case Comprehensive Cancer Center, a medical oncologist at the Cleveland Clinic Taussig Cancer Center in Ohio, nivolumab is now the treatment of choice when targeted drugs no longer work. Nivolumab's target, a protein called PD-1, is an immune checkpoint that shuts down T cells before they harm normal tissues. T cells attack with such ferocity that they rely on checkpoints such as PD-1 to keep them under control. But tumours can exploit this mechanism to protect themselves. Located on T-cell surfaces, PD-1 attaches to a receptor called PD-L1 on cancer cells. That binding tricks T cells into no longer viewing tumours as foreign. Nivolumab blocks PD-1 from attaching to PD-L1, and thus exposes cancer cells to an immune attack.
|
REQUEST FOR PROJECT PROPOSALS: Ohio Brain Tumor SPORE
Deadline: Oct 14
All investigators are invited to submit concept proposals for five-year projects to compete for incorporation as a full project proposal in the resubmission of our Ohio Brain Tumor SPORE application. All proposals should be directed towards translational research of brain tumor malignancies, with at least one specific aim that involves direct study of patients or of human tissues.
Proposals must include at least two project leaders: one Basic Science leader and one Clinical leader. Maximum Funding Level -$210,000/year direct cost for 5 years ($1,050,000 total direct costs).
Concept Proposal Guidelines:
- Contact information for PI and faculty collaborators
- Proposal (up to 5 pages) in length (excluding references)
- Background and significance (1-2 pages)
- Experimental Design (2-3 pages)
- NIH biosketches for all faculty participants
Completed proposals must be emailed to Yingli Wolinsky (yxh36@case.edu) by October 14.
|
Limited Submission: NSF Major Research Instrumentation Program
LOI Deadline: Oct 14
External Deadline: Jan 11, 2017
The
National Science Foundation (NSF) Major Research Instrumentation Program (MRI) serves to increase access to shared scientific and engineering instruments for research and research training in our Nation's institutions of higher education, and not-for-profit museums, science centers and scientific/engineering research organizations. This program especially seeks to improve the quality and expand the scope of research and research training in science and engineering, by supporting proposals for shared instrumentation that fosters the integration of research and education in research-intensive learning environments. Each MRI proposal may request support for the acquisition (Track 1) or development (Track 2) of a single research instrument for shared inter- and/or intra-organizational use; development efforts that leverage the strengths of private sector partners to build instrument development capacity at MRI submission-eligible organizations are encouraged.
|
Limited Submission Opportunities for Pilot Projects in Non-AIDS Defining Cancers
Deadlines: Oct 24, 2016 and Feb 27, 2017
Award Description:
- Funding for research teams with a focus on unique aspects of aging and NADC in HIV positive patients
- FOUR research projects will be awarded over two rounds of funding
- Each research project will be funded at a level up to $50,000 for one year.
|
University Hospitals and the Case Coulter Translational Research Partnership Infectious Disease Pilots
Deadline: Nov 1
The Case Coulter Translational Research Partnership and University Hospitals are offering a collaborative pilot award opportunity to promote the development of new translational research projects between problem owners (clinicians) and solution providers (engineers). The target areas for funding are in the infectious disease domain.
Total funding of $50,000 is available for this program. Award budgets of $10,000-$50,000 may be requested. Awards will be funded for a period of six months to one year. Between one and three applications are expected to be accepted.
Applicants should propose novel solutions to the clinical problems below:
- Central line related bloodstream infections: Central lines not only allow delivery of continuous fluids, therapies and food to critically ill patients while in the hospital, but also receive therapies at home. In caring for these semi-permanent lines, meticulous attention to infection prevention processes is needed to assure that bacteria (leading to life-threatening infections) does not enter the lines.
- Surgical site infections: Surgical site infection (SSI) continues to represent a significant portion of health care-associated infections. The impact on morbidity, mortality and cost of care has resulted in SSI reduction being identified as a top national priority in the U.S. Department of Health and Human Services Action Plan to Prevent Healthcare-Associated Infections.
- Emerging Infectious Diseases: Each time a solution for antimicrobial therapy or eradicating diseases is developed through the use of vaccines, there is an evolution in the microbes that causes new diseases appear, such as Methicillin-resistant Staphlococcus aureus.
The submitting co-PI is required to be a full-time CWRU engineering faculty member with an appointment in biomedical engineering.
The clinical co-PI will be matched to the program after the review process is completed. The submitting co-PI may include suggestions for the clinical co-PI.
|
Susan G. Komen Inflammatory Breast Cancer
Deadline: Nov 28
A major goal of this partnership is to promote innovative ideas to expand the knowledge of IBC and develop innovative new treatments. An additional goal is to attract new investigators from diverse disciplines to apply their expertise to the IBC field. Therefore, in addition to established IBC investigators, we encourage investigators from all fields to submit proposals for innovative IBC research, regardless of prior research experience.
These Inflammatory Breast Cancer Research Grants are intended to stimulate the exploration of new ideas and novel approaches to the field of IBC research that have significant potential to rapidly improve our understanding of IBC and TNBC. This program will consist of two stages. In the first stage, one year of funding will be awarded to allow investigators to establish the foundation of a robust and innovative IBC research project. In the second stage, awardees will have the opportunity to compete for additional funding to build upon their original project.
|
Sidney Kimmel Foundation Awards Program
Deadline: Dec 1
Kimmel Scholar Award
To select grant recipients, the Sidney Kimmel Foundation has created a Medical Advisory Board consisting of distinguished cancer researchers. Each year, the Kimmel Foundation expects to select up to 10 grant recipients who will each receive $100,000 per year for two years. Qualified applicants must hold an MD, PhD or equivalent graduate degree and must perform research in an American not-for-profit institution during the period of Kimmel Foundation support.
The Kimmel Foundation is seeking accomplished young investigators dedicated to a career in cancer research. Applications are limited to those who achieved the equivalent rank of Assistant Professor on or after July 2013. However, physicians who have both clinical and research responsibility are eligible if appointed on or after July 2012. These awards are designed for researchers who do not yet have their own R01 funding. Applicants will be judged on the basis of quality of prior work, research proposed and letters of support. Funding of awards will be subject to execution of binding agreements setting forth terms and conditions under which scholarships will be provided. Applicants for 2017 awards will be notified by mid-April 2017.
Kimmel Translational Science Awards
The Foundation provides up to five additional awards specifically for physicians engaged in translational science. Eligibility includes those with an MD or equivalent degrees, who have achieved the rank of Assistant Professor on or after July 2012. Candidates must not hold R01 funding for the laboratory component of their cancer research. Applicants must demonstrate a significant personal involvement in the laboratory component of the translational project described. The translational research may involve primarily animal studies but must include reasonable application to subsequent human investigation.
|
HHMI Hanna H. Gray Fellows Program
Deadline: Feb 1, 2017
The Howard Hughes Medical Institute (HHMI)
Hanna H. Gray Fellows Program seeks to increase diversity in the biomedical research community by recruitment and retention of individuals from groups underrepresented in the life sciences. Through their successful careers as academic scientists, Hanna H. Gray Fellows will move science forward and inspire the next generation of scientists from America's diverse talent pool. The Institute will select and support up to 15 Fellows in this first competition, which is now open for applications.
Fellows will receive funding for their postdoctoral training and, if eligible, in their early career years as independent faculty. The program includes opportunities for career development, including mentoring and active involvement in the HHMI scientific community.
|
Request for Proposals for Case CCC Funding for Pilot/Phase I Clinical Trials
Deadline: Open
The Case CCC is encouraging investigators to submit Letters of Intent (LOI) for
Early Phase Clinical Research Support (EPCRS) funding. These in-house funds are available for the conduct of early phase clinical trials of relatively short duration. Priority will be given to trials which are developed jointly between UH and CCF with planned accrual at both institutions.
The proposals are being accepted on a rolling basis subject to availability of funds.
Please direct any questions and/or submit LOIs to Katarzyna Karelus, Case CCC Clinical Research Office,
katarzyna.karelus@case.edu, 216.844.4176.
|
NIH BULLETIN- Notices and Funding Opportunities
|
|
|
FOLLOW US
|
|
Fri, Oct 14
8a Breen Conf Rm
TCI Grand Rounds
Charles Rudin, MD
Memorial Sloan Kettering
"New Therapeutic Targets for Small Cell Lung Cancer"
8a R3/002-003 Cleveland Clinic
Cancer Center Seminar Series
John Letterio, MD
Chief, Division of Pediatric Hematology and Oncology, UHCMC and Rainbow Babies and Children's Hospital
Professor, Pediatrics, CWRU
Member, Hematopoietic and Immune Cancer Biology Program, Case Comprehensive Cancer Center
12p BRB 105
Radiation Oncology Grand Rounds
Jennifer Bellon, MD
Director, Breast Radiation Oncology, Dana-Farber Cancer Institute
Associate Professor, Radiation Oncology, Harvard Medical School
"Radiation Therapy for Early -Stage Breast Cancer: One Size Does Not Fit All"
12p Lerner B-151
Cancer Center Research in Progress
Abbey Perl
Graduate Student, Narla lab, Pharmacology
Narla Lab, CWRU
"Defining the role of the PPP2R3A regulatory subunit gene in PP2A's tumor suppressive activity"
4p WRB 3-136
|
|
Mon, Oct 17
Case CCC DNA Damage and Repair
12p Wearn 137
GMI Seminar
Nick Sarn
Eng Lab, Genomic Medicine
Cleveland Clinic
"Characterizing the potential roles of TMEM181 in neurodevelopment and ASD"
12:30p NE1-205 Cleveland Clinic
Cancer Center Research Chalk Talk
Zhenghe John Wang, PhD
AND
Drew Adams, PhD
1p WRB 3-136
DPB Seminar
Eric Gouaux, PhD
Investigator, Howard Hughes Medical Institute
Senior Scientist, Vollum Institute
Jennifer and Bernard Lacroute Term Chair in Neuroscience Research, Oregon Health & Science University
"Music of the brain illuminated by molecular studies of the instruments: X-rays and electrons reveal architecture and mechanism of neurotransmitter receptors and transporters"
4p SOM / Robbins Building, E-501
|
|
Tues, Oct 18
Sangeeta Kumari, PhD
Research Fellow, Heemers Lab, Cancer Biology
Cleveland Clinic
"Coregulator-Dependent Interaction Between AR and p53: A Prospective Therapy for Prostate Cancer"
2p NC1-202 Cleveland Clinic
|
|
Wed, Oct 19
8a Lerner B-151
Radiation Oncology Grand Rounds
Jennifer Bellon, MD
Director, Breast Radiation Oncology, Dana-Farber Cancer Institute
Associate Professor, Radiation Oncology, Harvard Medical School
"Radiation Therapy for Early -Stage Breast Cancer: One Size Does Not Fit All"
8:10a Lerner B-151
Immunology Seminar Series
Tara DeSilva, PhD
Immunology, Cleveland Clinic
1p NC1-202 Cleveland Clinic
Great Lakes Nuclear Receptor Conference
4:30p Tinkham Veale University Center
|
|
Thurs, Oct 20
Great Lakes Nuclear Receptor Conference
8:30a-6p Tinkham Veale University Center
Neurosciences, Molecular + Microbiology, Biological Sciences and Oral Medicine Seminar
Mohanish Deshmukh
University of North Carolina Chapel Hill
12:30p SOM E301
|
|
Fri, Oct 21
8a Breen Conf Rm
TCI Grand Rounds
8a R3/002-003 Cleveland Clinic
Cancer Center Seminar Series
12p BRB 105
Cancer Center Research in Progress
4p WRB 3-136
|
|
Mon, Oct 24
Cancer Biology Seminar
Wei Wei
Zhang Lab, Genomic Medicine
Cleveland Clinic
"Growth retardation in SEC23B deficient mice: disruption of the growth hormone signaling pathway"
12:30p NE1-205 Cleveland Clinic
|
|
Tues, Oct 25
THOR Seminar
Man-Sun Sy, PhD
"The Good, The Bad, and The Ugly of Prions"
1p R3-027 Cleveland Clinic
|
|
Wed, Oct 26
8a Lerner B-151
CDDRCC Seminar
Massarat Zutshi, MD
Department of Colorectal Surgery
Cleveland Clinic Foundation
12p NA1-142 Cleveland Clinic
|
|
Thurs, Oct 27
Neurosciences Seminar
James Shorter
University of Pennsylvania
"Protein disaggregase modalities to counter neurodegenerative disease"
12:10p BRB 105
Molecular Biology and Microbiology Seminar
Tomoaki Ogino, PhD
Assistant Professor, Molecular Biology & Microbiology
Case Western Reserve University
1p W203 (Rottman Seminar Room)
Case CCC Clinical Research Retreat
5:30-7:30p Cleveland Clinic R3-002/003
|
|
Fri, Oct 28
8a Breen Conf Rm
TCI Grand Rounds
8a R3/002-003 Cleveland Clinic
Cancer Center Seminar Series
12p BRB 105
Cancer Center Research in Progress
4p WRB 3-136
|
ADDITIONAL UPCOMING SYMPOSIUMS & EVENTS
Case Comprehensive Cancer Center Clinical Research Retreat
October 27
5:30-7:30p
Cleveland Clinic
R3-002/003
|
PREVIOUSLY ANNOUNCED OPPORTUNITIES
Application Deadline:
Nov 15
LOI Deadline:
Feb 1, 2017
Deadline: Open
Deadline: Open
Deadline: Open
|
|
 |
|
